AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00539799
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 - 7.5 mg/day
Trial: NCT00539799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo to prednisolone
Trial: NCT04808778
Drug: Hydroxyurea therapy per standard care
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose of 20mg/kg/day
Trial: NCT05658406
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of 15 mL/kg/hour Ringer's lactate intraoperative
Trial: NCT05658406
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
Trial: NCT05658406
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
Trial: NCT06316206
Drug: Ethinylestradiol/Dienogest 0.03mg/2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
Trial: NCT05213676
Drug: Inhaled Nitric Oxide (iNO) use
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
Trial: NCT04925492
Drug: Cu-64]-LLP2A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A radioactive tracer used in PET imaging.
Trial: NCT05068076
Drug: Perfluorobutane
RxNorm normalized name: Perfluorobutane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
Trial: NCT00316641
Drug: Lipid-lowing Tea
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06373744
Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
Trial: NCT05230680
Drug: ACHOP
RxNorm normalized name: ACHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total
Trial: NCT06259058
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m² on Day 1 of a 14-day cycle
Trial: NCT05470387
Drug: LB1148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 700 mL of drug product will be administered orally as a split dose before surgery.
Trial: NCT05470387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Trial: NCT06318897
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06318897
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT05180695
Drug: HDM201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.
Trial: NCT04199728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection pen
Trial: NCT05201404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm
Trial: NCT05745311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00005674
Drug: Creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05783206
Drug: MIR 19 ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs.
Trial: NCT05502913
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
Trial: NCT05932277
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05932277
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06194734
Drug: KC1036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle
Trial: NCT05489406
Drug: F/TAF TOS (3 x 60/7.5 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60/7.5 mg TOS emtricitabine/TAF
Trial: NCT00034463
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05608343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Difamilast (Study drug) ointment without active ingradient
Trial: NCT03749850
Drug: LTLD
RxNorm normalized name: Levodopa and Carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol.
Trial: NCT03749850
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive up to six cycles at three-weeks intervals of:~- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol.
Trial: NCT04701333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05011227
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
Trial: NCT00962481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05622656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride Solution
Trial: NCT04984070
Drug: Oral Contraceptives, Combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
Trial: NCT04878198
Drug: Melatonin supplement intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
Trial: NCT05375188
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
Trial: NCT05844449
Drug: VNZ/TEZ/D-IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration.
Trial: NCT06020898
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
Trial: NCT05055544
Drug: Bearberry
RxNorm normalized name: bearberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
Trial: NCT05625334
Drug: non-enteric-coated chewable aspirin
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally administered
Trial: NCT05174065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT05803850
Drug: HNC1058 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
Trial: NCT05839574
Drug: MTX monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
Trial: NCT05567822
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
Trial: NCT05206149
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo (represented by isotonic saline solution) is administered.
Trial: NCT05571046
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)
Trial: NCT05051579
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05051579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05062005
Drug: Induction Chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.
Trial: NCT05692024
Drug: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
Trial: NCT05692024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
Trial: NCT04790734
Drug: Sedation drugs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different sedation drugs
Trial: NCT06115993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT05362110
Drug: HCP1803-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT05362110
Drug: RLD2002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT05362110
Drug: HPP2003-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Trial: NCT05362110
Drug: HPP2004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Trial: NCT05299398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily
Trial: NCT05404243
Drug: phenolization
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In case of phenolization group, an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
Trial: NCT05924958
Drug: Eprolidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
Trial: NCT04811703
Drug: Combined PIPAC / IV chemotherapy treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
Trial: NCT06533878
Drug: HY-209
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
Trial: NCT06085534
Drug: LNK01001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral use
Trial: NCT06085534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral use
Trial: NCT05505448
Drug: REGN14284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
Trial: NCT05505448
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending IV or SC administration per the protocol
Trial: NCT04763044
Drug: 250 ppm F as MFP
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Trial: NCT04763044
Drug: 1100 ppm as MFP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Trial: NCT04763044
Drug: 2800 ppm F as MFP
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Trial: NCT04763044
Drug: 1100 ppm SnF2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be assigned to this treatment during the fifth period for this crossover study.
Trial: NCT04968158
Drug: Acetaminophen 325 mg / Tramadol 37.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet, every 8 hours of 325 mg/ 37.5 m
Trial: NCT05975749
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Trial: NCT04703088
Drug: 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
Trial: NCT06444035
Drug: HA35 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
Trial: NCT06012682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin
Trial: NCT01132794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal nasal saline
Trial: NCT00798616
Drug: prednisolone or methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
Trial: NCT00798616
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral or IV placebo
Trial: NCT04874935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
Trial: NCT05054140
Drug: Placebo matching IMU-838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching IMU-838 tablets
Trial: NCT04172376
Drug: Conservative medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
Trial: NCT05813860
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.
Trial: NCT04921566
Drug: Toradiur® tablet 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toradiur® is manufactured by MEDA Manufacturing Cologne, Germany. Each tablet contains 10 mg of torasemide.
Trial: NCT05190419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT05310760
Drug: Vit C
RxNorm normalized name: M-Vit Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
Trial: NCT02528708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution
Trial: NCT05117736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
Trial: NCT06164743
Drug: VVN461 Ophthalmic Solution 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular drug
Trial: NCT06164743
Drug: VVN461 Ophthalmic Solution 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular drug
Trial: NCT06164743
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular drug
Trial: NCT04920617
Drug: CPA
RxNorm normalized name: MCPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg twice daily, week on then week off
Trial: NCT06371196
Drug: Babaodan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Babao Dan Capsule (State Drug License: Z10940006) is produced by Xiamen Traditional Chinese Medicine Factory Co., Ltd; Packing specification: 0.3g/capsule, 6 capsules/board×2 boards/small box; Ingredients are in vitro cultivated cowhide, snake gallbladder, antelope horn, pearl, panax ginseng, artificial musk, and so on. Intervention measures are really the original UDCA treatment program based on the addition of eight treasure Dan capsule, 2 capsules / times, tid, oral. Course of treatment: 3 months (based on 30 days/month).